Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Aix Marseille Univ, CNRS, ICR UMR 7273, 13385 Marseille CEDEX 05, France.
IHU Méditerranée Infection, UMR VITROME, IRD, SSA, Mycology & Tropical Eucaryotic Pathogens, Aix Marseille Univ, 13005 Marseille CEDEX 05, France.
Molecules. 2020 Aug 27;25(17):3929. doi: 10.3390/molecules25173929.
From three previously identified antiplasmodial hit compounds (-) and inactive series (), all based on a 2-trichloromethylquinazoline scaffold, we conducted a structure-activity relationship (SAR) study at position four of the quinazoline ring by synthesizing 42 novel derivatives bearing either a carboxamido- or an alkoxy-group, to identify antiplasmodial compounds and to enrich the knowledge about the 2-trichloromethylquinazoline antiplasmodial pharmacophore. All compounds were evaluated in vitro for their cytotoxicity towards the HepG2 cell line and their activity against the multiresistant K1 strain, using doxorubicin, chloroquine and doxycycline as reference drugs. Four hit-compounds (EC K1 ≤ 2 µM and SI ≥ 20) were identified among 4-carboxamido derivatives (, , and ) and two among 4-alkoxy derivatives ( and ). Regarding the two most potent molecules ( and ), five derivatives without a 2-CCl group were prepared, evaluated, and appeared totally inactive (EC > 50 µM), showing that the 2-trichloromethyl group was mandatory for the antiplasmodial activity.
从之前鉴定的三种具有抗疟活性的化合物(-)和无活性系列()中,我们都基于 2-三氯甲基喹唑啉支架,在喹唑啉环的 4 位进行了构效关系(SAR)研究,通过合成 42 种新型衍生物,带有羧酰胺基或烷氧基,以鉴定抗疟化合物,并丰富关于 2-三氯甲基喹唑啉抗疟药效团的知识。所有化合物都在体外进行了细胞毒性测试,以评估它们对 HepG2 细胞系的细胞毒性,以及对多药耐药的 K1 株的活性,以阿霉素、氯喹和强力霉素作为参考药物。在 4-羧酰胺基衍生物(、、和)中鉴定出四种有效化合物(EC K1 ≤ 2 μM 和 SI ≥ 20),在 4-烷氧基衍生物(和)中鉴定出两种。对于两种最有效的分子(和),制备、评估了五个没有 2-CCl 基团的衍生物,它们完全没有活性(EC > 50 μM),表明 2-三氯甲基基团对抗疟活性是必需的。